The Wellington-based hospital is hoping to announce its first resident at the start of next year, who will work under the guidance of Fran Taylor-Brown and Tom Cardy.
This is the first residency programme to be conducted at Cave and has been launched by Fran who, along with Tom, is an EBVS and RCVS specialist in veterinary neurology.
Fran said: "The ECVN accreditation is an important milestone for us as we look to develop and expand our expertise in neurology.
"We are currently undertaking a major recruitment drive and having the capability to offer specialist training in this discipline is another feather in the cap.
"We’re hopeful this approval will open the door to allow clinicians in other disciplines to receive specialist-level training with us in the future."
Cave has also introduced an internship programme to support the growth of the team and has taken on Samantha Gilbert a graduate of James Cook University in Australia.
Novartis Animal Health has issued the following statement concerning the supply of acepromazine (ACP) injectable in the UK:
"Recent upgrades to Novartis Animal Health’s manufacturing plant in the UK have resulted in the site becoming a worldwide centre of excellence for the production of bulk liquids. This upgrade has had an impact on the manufacture of ACP 2mg/ml and 10mg/ml injectable products, which will no longer be produced in the UK.
From January 2011, Novartis Animal Health will no longer be able to supply ACP Injection 2mg/ml or ACP Injection 10mg/ml to wholesalers. However, it is not Novartis’ intention to discontinue the supply of acepromazine injectable; in order to ensure consistency of supply to the UK market the company will be importing the Vetoquinol French product Calmivet.
Calmivet is a monovalent acepromazine injection licensed for use in dogs, cats and horses, available as a 5mg/ml injection, 50ml vial.
In order to obtain Calmivet from wholesalers, veterinarians will need to apply for a free of charge Special Import Certificate from the VMD. This can be completed on line at www.vmd.gov.uk.
It is anticipated that this situation will continue for at least the first 6 months of 2011, until an alternative manufacturing site is established. As soon as we have more information on the timelines this will be communicated.
A full communication including a prep room reminder poster and Calmivet product leaflet has been mailed to all UK practices.
Vetoquinol UK are not responsible for the distribution or technical support of this product, so any queries should be directed to Novartis Animal Health UK on 01276 694402.
The production and supply of ACP Tablets 10mg remains unaffected."
The webinars already available cover subjects like cardiopulmonary resuscitation (CPR), emergency diagnostics and traumatic brain injury, presented by experienced emergency vets Aoife Reid, Liron Levy-Hirsch and Jacqueline Seymour.
More content is due to be added to the library in the coming weeks, including guest webinars from TVM UK on rodenticide and seizure management, and from clinical psychologists Dr Jo Becket and Dr Jess Brown on “thrive, not just survive” and “when stress gets too much”. There will also be a session from ECC specialist Tobias Grave (pictured right) on how to deal with some of the most common pet emergencies.
Tobias will also be on hand to help veterinary surgeons and nurses whose practices use Vets Now for their out-of-hours service with both general advice and a second opinion on potentially complex cases via the new support line.
Tobias said: “Covid-19 is bringing fresh challenges to vets and vet nurses every day. With clinicians seeing a caseload which is mainly emergency and often having to triage patients over the phone or by video consult, it’s never been so important to come together as a profession.
"Both our webinars and our specialist support line for practices who use our service will help equip vet professionals with the skills and knowledge needed to deal with challenging emergencies in practice."
You can find Vets Now’s library of free ECC webinars here.
Sarah, who practices at Southfields Veterinary Specialists, was already a European and Royal College Specialist in oncology. Now, after studying for a year and passing the European College of Veterinary Internal Medicine (ECVIM) exams this autumn, she has now been recognised as a European Specialist in radiation oncology as well.
Sarah said: "I intend to use my experience to grow the radiation and oncology service at Southfields and, with the benefit of our new linear accelerator and state-of-the-art hospital, deliver the most advanced treatment options for our veterinary patients.
"I also intend to use my experience and expertise to contribute to the further development of radiation oncology as a specialist qualification in Europe."
Congratulations Sarah!
The technology, developed by US firm SignalPET, sends X-rays through an AI machine algorithm to get a more or less instantaneous report, rather than needing a radiology specialist to analyse results, which can take up to three days.
IVC starting trialling the system with 22 of its practices last November and it quickly became clear that there were huge benefits, including saving time for clinicians, cost, and improving confidence in the diagnosis.
The majority of IVC's trial teams said they viewed the technology as a positive diagnostic aid, supporting their own professional opinion.
It also served as a learning tool, increasing the confidence and clinical independence of younger or newly qualified vets.
Sarah Merrell, Clinical Director at Lincvet, a group of IVC Evidensia practices in Lincoln and one of the trial clinics, said: “SignalPET has proved really valuable – giving us excellent support for radiography.
"It has been used by both our highly experienced and newly graduated clinicians to get a second set of ‘eyes’ on our cases giving reassurance and support when reading our radiographs.
“Overall, it has improved clinician confidence, reduced the pressure on senior vets, given us an additional tool for training and development, and greatly enhanced client understanding of our findings.”
Alistair Cliff, IVC Evidensia’s Deputy Chief Medical Officer, said: “The AI radiology process developed by SignalPET represents a real revolution in how results are analysed.
"The overwhelming success of our initial trial in November means we are confident in pushing ahead with rolling out the technology in the UK this year and eventually, in Europe too."
Rominervin contains 10 mg/ml romifidine hydrochloride, equivalent to 8.76 mg romifidine, presented in a 20 ml vial.
It can be used as a sedative to facilitate handling, examination, minor surgical interventions and minor procedures or as a premedication prior to administration of injectable or inhalation anaesthetics.
Rominervin can also be used in combination with synthetic opiates such as butorphanol to provide deeper sedation or analgesia.
Dechra Brand Manager Emma Jennings said: "Rominervin is highly effective as it has a longer duration of action than other alpha-2 agonists1. It starts to work within one to two minutes with maximum sedation achieved between five and 10 minutes.
"It is yet another valuable addition in our equine anaesthesia and analgesia range that has been designed to provide vets with the therapies they need to operate successfully in day-to-day practice."
Rominervin can be used in conjunction with Dechra’s equine anaesthesia and analgesia app, designed to help veterinary professionals choose optimal anaesthetic protocols and calculate anaesthetic drug doses and administration rates.
For more information visit: www.dechra.co.uk/products/equine
Andrew Parry MRCVS, an RCVS and European Specialist, heads Diagnostic Imaging at Willows. He said: "Our previous CT scanner was excellent but all technology moves on. We wanted to ensure we maintained our position at the forefront of specialist veterinary diagnostic imaging.
"We have a large cardiology service and the Siemens scanner, with its advanced cardiac imaging package, will allow the team to gain a huge amount of information about cardiac disease and other vascular abnormalities. This combination of technology and on-site Specialist imaging expertise is unusual, even at a referral level.
"A further advantage of the new scanner is its use of tin filters, which enables it to produce high quality images of regions of high contrast, such as feline chests."
Willows has also invested in a software package which does all sorts of clever stuff to bring the images to life for clients.
He said: “The syngo.via software allows anyone to access and manipulate images from any computer in the hospital. This can be building complex models or more straightforward multiplanar reconstruction.
"Specialists can show models to clients immediately, while surgeons can manipulate images in theatre and all clinicians can view and interact with images from their own working environment.
"Additionally, we have invested in Siemens-manufactured software called syngo.via Cinematic VRT, which means we can build, rotate and fly through volume rendered CT models with clients, giving them a dynamic understanding of anatomy and pathology."
Hysolv Animal Health has announced the launch of Salmovac 440, a new live salmonella vaccine for poultry which the company claims gives earlier, stronger and longer-lasting immunity than other salmonella vaccines.
The vaccine is given orally through the water supply in a three-dose regime that protects against Salmonella Enteritidis (SE) and Salmonella Typhimurium (ST). It also protects against other SE strains and the newly-emerging monophasic Salmonella Typhimurium strains.
Hysolv says the advantage for farmers is that the vaccine strain is robust and can survive in more hostile conditions. It therefore remains effective where the water delivery system is less than ideal.
The first dose is administered from Day 1 followed by a second dose at six weeks and a third as early as 11 weeks. Salmovac 440 protects chicks after six days and remains effective for up to 63 weeks after the third vaccination, providing an extra four weeks of protection.
Hysolv says another important benefit to egg producers is that the earlier final vaccination at 11 weeks means that the birds can be moved into the laying house as early as 16 weeks old if required — a significant management advantage on some farms.
During the development of the vaccine it was found that the third live vaccination tended to ‘shut down’ any prolonged shedding of the vaccine strain. This, coupled with the earlier vaccination at 11 weeks, helps solve the issue of the vaccine strain being found at transfer to the layer house. Dr Daniel Windhorst, salmonella vaccine specialist with IDT Biologika, said: "If any should be found, the new PCR (Polymerase Chain Reaction) test shrinks the testing time to just two to three hours."
Daniel added: "Although the UK has one of the lowest percentages of salmonella in its flocks, almost one-third of cases were of S Typhimurium. In most continental countries the percentage is much higher, so the extra cover provided by this vaccine is important."
Salmovac 440 has been approved for use by the British Egg Industry Council, which administers the Lion Code.
VetSurgeon member Shailen Jasani MA VetMB MRCVS DipACVECC has launched the Ralph site (theralphsite.com), a website offering support and advice to those coping with pet bereavement.
The site contains forums, downloadable advice sheets, a directory of crematoria and cemeteries, and offers owners the ability to create a memorial for their pet.
The Ralph site was named after Shailen's own cat, which died after a car accident in 2010. Shailen funded the setup of the site, and it is a not-for-proft.
Merial Animal Health has announced that it has purchased the the anti-inflammatory treatment for lameness in horses, Hyonate® (sodium hyaluronate), from Bayer.
Merial's equine marketing and technical manager, Louise Radford MRCVS said: "Hyonate is an established treatment of lameness in horses due to non-infectious inflammation of joints, using both intra-articular (IA) and intravenous (IV) injection.
"The beneficial effects of HA supplementation are attributable to the anti-inflammatory effects, improvement in viscoelastic properties of the synovial fluid, and interaction with the synovial membrane affecting pain transmission and joint metabolism¹."
For more information telephone Customer Support on 0870 6000123 or contact your local Merial Equine Specialist.
Reference
The company says the new product has been 10 years in development and uses 'Soft Mist' technology - developed originally for human use by its pharma business - to deliver medication deep into the horse's lungs.
The active ingredient in the Aservo EquiHaler is ciclesonide, a corticosteroid that is activated directly in the lung, reducing the lower airway inflammation associated with severe equine asthma and reducing the risks commonly associated with systemic corticosteroids.
The Aservo EquiHaler does not use a propellant, so it does not contribute to greenhouse gas emissions. Boehringer also highlights that it is made from up to 50% recycled materials. In April, the product was awarded a Red Dot Design Award.
Dr Marc Laemmer, Head of Equine in UK & Ireland said: "It's another industry first and is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation.
"We understand that a product launch in this challenging time for the veterinary profession may seem surprising, but we have had such strong demand from equine vets for the product that we have committed to making Aservo EquiHaler available. Out team of territory managers and vet advisers will conduct remote meetings with customers to make sure that they have the information and support they require."
Dechra Veterinary Products has announced that it will be launching Zycortal, a new medication for the treatment of canine hypoadrenocorticism at the BSAVA Congress in April.
Zycortal is a prolonged-release suspension used as replacement therapy for mineralocorticoid deficiency in dogs with Addison’s disease. Dechra says it has proved highly effective in clinical trials with more than 80% of dogs responding positively to treatment1.
Zycortal contains desoxycortone pivalate (DOCP) which Dechra says controls serum electrolytes more effectively than fludrocortisone2 (the human treatment currently prescribed for dogs with Addison’s disease) and is considered the preferential drug for mineralocorticoid supplementation.
Zycortal is the only European licensed treatment for canine hypoadrenocorticism and adds to Dechra’s existing endocrinology range.
Visitors to the BSAVA Congress will be able to find out more about Zycortal at the Dechra stand (500). Delegates are also invited to attend a presentation by Professor Ian Ramsey BVSc PhD DSAM DipECVIM-CA FHEA MRCVS on Saturday, April 9, at 11.10am.
The presentation, New developments in the diagnosis and management of Addison’s disease aims to give delegates an insight into the condition.
Dechra Brand Manager Craig Sankey said: "We are very excited to be able to bring Zycortal to veterinary professionals in the UK. Addison’s disease can be very hard to diagnose as it mimics so many other illnesses.
"Each injection of Zycortal lasts approximately one month, providing long-term control of primary Addison’s disease. The prognosis for dogs with Addison’s disease is excellent provided that treatment is maintained for life. Our team will be on hand at the BSAVA Congress to explain and discuss the benefits that Zycortal can bring to their day to day practice in the fight against this illness."
References
Zoetis has announced the launch of Versican Plus, a vaccine range for dogs in the UK and throughout Europe.
Versican Plus is the only vaccine to combine DHPPi + L4 in a single injection1, something which Zoetis says is the fruit of several years research and development.
The leptospirosis components of the vaccine have been designed to meet the challenges of both existing and emerging types.
According to the company, Versican Plus is the only tetravalent leptospirosis vaccine to deliver prevention against clinical signs and urinary excretion of established (Icterohaemorragiae and Canicola) and emerging (Bratislava and Grippotyphosa) canine leptospirosis (except Grippotyphosa where prevention of clinical signs occurs but with a reduction in urinary excretion).
Zoetis also highlights the advantage this vaccine brings is in its viral components. Versican Plus utilises a new CPV-2b strain, the most prevalent strain in the UK2, to prevent clinical signs, leucopoenia and viral excretion caused by Parvovirus.
Practices using Versican Plus will have the ability to provide protection at the earliest opportunity, as it has been proven to be protective against virulent challenge in the presence of maternally derived antibodies to Parvovirus, Distemper and Adenovirus at levels equal or higher to those likely to be encountered under field conditions.
As a result Versican Plus can be used from 6 weeks of age with an early onset of immunity being achieved for Parvovirus, Distemper and Adenovirus at 9 weeks. Parainfluenza and Leptospirosis immunity follow shortly thereafter at 12 and 13 weeks respectively.
Following primary vaccinations three to four weeks apart Versican Plus provides 3 years duration of immunity for Parvovirus, Distemper and Adenovirus.
Ned Flaxman, Zoetis UK Companion Animal director said: “Our research and development team has taken many different aspects of vaccination into account to create Versican Plus. As well as offering comprehensive protection in accordance with the current epidemiological situation, the vaccine is also convenient to use. It offers a flexible primary vaccination course with an early finish option from 9 weeks, important for early socialisation reasons.”
For further information, visit www.zoetis.co.uk/versicanplus, contact your Zoetis Account Manager or telephone 0845 300 8034.
Ceva has announced the launch of Zodon®, a flavoured clindamycin for dogs and cats.
Zodon is the only veterinary licensed flavoured clindamycin available in the UK.
Zodon is indicated for the treatment of infected wounds and abscesses in cats and dogs and oral cavity/dental infections caused by or associated with clindamycin-sensitive species of Staphylococcus spp, Streptococcus spp in dogs.
Rob Mclintock, Business unit manager for Ceva said: "Zodon is an exciting new product for Ceva, it is the first clindamycin on the market to offer flavoured presentations designed to help deal with compliance issues and help improve treatment success."
In a palatability study 98.3% of dogs took Zodon chicken flavoured tablets spontaneously. Ceva says the oral solution for cats and small dogs also offers easier administration with grilled meat flavouring and a graduated syringe.
Adelaide Ellerington, product manager for Ceva Animal Health said: "Zodon complements our existing antibiotic range perfectly. The whole range is designed specifically for veterinary use allowing veterinary surgeons to dose more accurately and improve patient compliance by offering flavoured tablets and solutions."
You can preorder Zodon now from Ceva - telephone 01494 781510 or email: cevauk@ceva.com - alternatively Zodon will be available from wholesalers at the start of next week.
The Government says that contracts have been secured with Brittany Ferries and DFDS to run ferries into and out of Poole, Portsmouth, Plymouth, Immingham and Felixstowe, thereby relieving pressure on the Dover straights.
Critical goods have been identified as those essential for the preservation of human and animal welfare, including all veterinary medicines authorised under the Veterinary Medicines Regulation 2013, including finished and un-finished products, and Active Pharmaceutical Ingredients (for import and export).
Critical goods also include unauthorised medicines permitted for import under the Veterinary Medicines Directorate’s Special Import Scheme (for import only).
Photo: Shutterstock/Peter Hermes Furian
The programme commences in October 2017 and includes ten days of hands-on practical training based at the CPD Solutions Training Centre in Studley near Birmingham, where surgery tutors will help veterinary surgeons refine their techniques in small group sessions.
CPD Solutions says the main differences with existing PgCert programmes include a stronger emphasis on practical training, a lack of lecture days and the grouping together of practical days in three attendance sessions.
The company says that many current PgCerts run for 2 to five years, so its programme provides an opportunity for those who'd prefer to complete their training and gain a PgCert qualification in a much shorter timeframe.
Susie Coughlan, MD at CPD Solutions said: "Our experience is that vets get the most out of hands-on practical training in a structured and supportive environment, combined with reflective application of their new skills in practice. We set out to replicate this with the new PgCert – all attendance sessions are practical, and the course provides support for developing reflective work-based learning that vets can then use throughout their careers."
David Perrin, Head of Professional Development at the Centre for Work-Related Studies at Chester University said: "The University is proud to be working with CPD Solutions as leading educationalists in the field of veterinary professional development. We have put together a high-quality product that brings together our work-based learning expertise with CPD Solutions specialist knowledge, and this will be of wide interest to practitioners in the field."
For more information, contact CPD Solutions on 0151 328 0444 or visit www.pgcertsurg.com
Ceva Animal Health has launched Amodip, described as the first ever cat-friendly amlodipine licensed for veterinary use for the treatment of hypertension in cats.
Amodip is a chicken-flavoured, two-way break chewable tablet; its 1.25mg tablet size is designed for accurate dosing of cats, with a two-way break for administering 0.625mg to smaller cats. Each box contains 100 tablets in blister packs.
Ceva says these features should make it easier for pet owners to be compliant with the recommended treatment protocol and ensure that each cat is getting the right dose, reducing the risk of side-effects.
Amodip will be supported by videos and literature on how to measure hypertension in practice easily and with less stress, written by the International Society of Feline Medicine (ISFM).
For further information or to request copies of the ISFM hypertension materials, contact your local Ceva Animal Health territory manager or call 01494 781510.
BVA’s Voice of the Veterinary Profession survey panel, which polls over 1,000 UK vets, highlighted that many vets support the higher welfare standards of British farming, with 9 out of 10 vets saying they would be more likely to buy food if it was labelled as British or locally sourced. Over three quarters of vets said that they would be more likely to buy free-range (77%) or food that carried a Farm Assurance Scheme label (over 50% for Red Tractor and RSPCA Assured; formerly known as Freedom Food).
BVA President Sean Wensley encouraged consumers to check labels as the warmer weather sees BBQs and picnics take centre stage in gatherings of families and friends. He said: "Animal welfare should be a paramount consideration whether we’re thinking about purchasing pets or the food we eat. For vets it’s a top priority that the animals we rear for food have a good life and a humane death.
"Vets are not alone in caring about where their food comes from. To support high standards of animal welfare, all of us can vote for good animal health and welfare through our thoughtful meat, fish, and dairy purchases and send a strong message to food producers and retailers this summer."
BVA’s Voice of the Veterinary Profession survey panel also revealed that 9 out of 10 vets would be less likely to buy meat or fish if it was labelled as not stunned prior to slaughter.
BVA is leading a campaign to end slaughter without pre-stunning for animal welfare reasons and calling for better labelling of food to help consumers make pro-animal welfare choices.
To find out more about BVA’s campaign to end non-stun slaughter, visit: http://www.bva.co.uk/News-campaigns-and-policy/Campaigns/An-end-to-non-stun-slaughter
Image: CC BY-SA 2.0 cyclonebill
The company says this means that using Solacyl as an alternative to antibiotics could reduce overall antibiotic use by 4.4 tonnes a year.
The research was carried out by dairy veterinary consultant Owen Atkinson BVSc DHCP MRCVS, an RCVS recognised specialist in cattle health and production, at three English calf rearing units between November 2017 and May 2018. It involved four groups of beef calves from different dairy farms.
The 258 calves were given Solacyl (sodium salicylate) in-feed on the five days immediately upon arrival at the units (a high-risk period for animals to contract bovine respiratory disease).
According to Dechra, the use of Solacyl resulted in a reduction in antibiotic use of between 16% and 73% (based on doses), depending on the farm. Across all groups, the reduction was 43%.
Dechra says that neither the health of the calves nor the profitability of the rearing operations were compromised.
Owen Atkinson said: "I was involved in analysing the data and the data showed that there was no significant difference in growth rates or in mortality or in days to reach a target weight in the calves that had Solacyl, compared to previous batches of calves that had followed a prophylactic antibiotic protocol.
"I think this is an ideal protocol for those farmers who are competent, who are able to spot early pneumonia symptoms and are prepared to perhaps treat a slightly higher proportion of calves than they would otherwise have treated. They can now do that with higher confidence that their results should be as good as if they had used prophylactic antibiotics."
Dechra Farm Animal Veterinary Adviser Alana McGlade BVmedsci (hons) BVM BVS MRCVS added: "Sodium salicylate has the same fever-controlling, pain-managing and inflammation-reducing benefits in livestock as aspirin can have in humans.
"It can be administered conveniently to groups of animals, which means it can be given prior to known stress points in animals’ lives. This can be continued through and after those events, providing a welfare benefit and reducing the risk of a loss of appetite and its resulting effects.
"Solacyl can be administered without the supervision of a vet and that makes it a cost-effective and practical solution for farmers that can lead to a notable reduction in routine antibiotic use whilst protecting the welfare of a herd."
Dechra has now published a white paper which you can download here: "Enhancing welfare and combating antimicrobial resistance while maintaining productivity on calf units".
The results of the research will be presented at the BCVA Congress in October 2018.
The RCVS has opened a consultation on the future of veterinary specialisation, which includes a proposal that the use of postnominals and titles by veterinary surgeons should be rationalised in order to avoid confusion amongst the public.
The proposals are submitted for comment by the RCVS Specialisation Working Party, which is chaired by former Chief Medical Officer Professor Sir Kenneth Calman.
The Working Party's review was precipitated by a finding that the structure of veterinary specialisation is "confusing and opaque" to both animal owners and the profession (Unlocking Potential - a Report on Veterinary Expertise in Food Animal Production, by Professor Philip Lowe, 2009).
The Working Party has explored the routes to RCVS Recognised Specialist status. It has also looked at the use of 'specialist' more broadly, given the fact that it is not a protected term in the veterinary field, and has considered animal owners' expectations of a 'specialist'.
The Working Party also makes proposals for encouraging more veterinary surgeons to become specialists, given that there are currently only 319 on the RCVS List of Recognised Specialists, out of a UK practising arm of the profession of some 17,400 veterinary surgeons.
The proposals from the Working Party could have far-reaching impact. One suggestion is that all those meeting the criteria for specialist status would also become Fellows of the RCVS (FRCVS) - a status currently only held by those who complete a thesis or exam, or who qualify on the basis of 'meritorious contributions to learning'. There are also proposals that the term 'RCVS Recognised Specialist' be dropped and replaced with the much simpler term 'specialist' or 'veterinary specialist'.
Further proposals include the introduction of a 'middle tier' of veterinary surgeons - potentially to be called 'advanced practitioners' - who would be below full specialist status and subject to periodic revalidation.
There are also recommendations that veterinary surgeons should be obliged to explain referral options to their clients, including the level of expertise of those to whom they are referring cases.
The future of the RCVS subject boards, which currently manage the various Certificate and Diploma examinations, is also considered in the proposals.
The emphasis throughout is on simplification and improvement, according to Professor Sir Kenneth Calman, who said: "New legislation to introduce statutory registration for veterinary specialists would no doubt make things clearer, as it is for doctors and dentists, but, in the meantime, we believe there are a number of actions which the RCVS could take to improve matters."
The consultation paper can be downloaded from www.rcvs.org.uk/consultations, and comments are welcomed from members of the public, veterinary surgeons and veterinary nurses. The closing deadline for comments, which should be sent to RCVS Head of Education, Freda Andrews, on f.andrews@rcvs.org.uk, is Friday 9 December.
Comments received will be considered by the RCVS committees and Council in early 2012.
Following legislative changes, the British Veterinary Association has updated its 'Good Practice Guide to Handling Veterinary Waste' for England and Wales.
Supported by the Environment Agency the Guide primarily consists of a quick-reference poster enabling vets to categorise and segregate veterinary waste in line with Environment Agency requirements. The poster defines the types of hazardous waste, outlines the types of containers required and sets out the appropriate classification codes.
The Guide is complemented by more detailed web guidance which incorporates useful templates to download.
BVA President Carl Padgett said: "All businesses have a duty of care to ensure that all waste is stored and disposed of responsibly, that it is only handled or dealt with by those authorised to do so and that appropriate records are kept of all waste that is transferred or received.
"The BVA Guide has been a popular resource for the profession since we first launched it in 2008 making it considerably easier for vets to comply with Hazardous Waste Regulations. The revised poster is hopefully an incentive for practices to check if their requirements have changed and ensure they're still up-to-date."
The poster and web advice are available at http://www.bva.co.uk/activity_and_advice/1641.aspx and BVA members will receive a hard copy of the poster to display in their practice.
Dr Bohnen faced two charges. The first was that in March 2017, she failed to attend to Belle, a Cavalier King Charles Spaniel, in order to provide appropriate and adequate care including: assisting Belle with urination, monitoring her with a view to considering alternative treatment options, and monitoring her with a view to providing her owners with an update on her condition.
The second charge was that Dr Bohnen later claimed dishonestly that she had attended to the animal, both to the owners, in clinical records hospital records, in a note provided to colleagues and during internal disciplinary proceedings held at her practice.
At the outset of the hearing the Committee considered an application from Dr Bohnen for the hearing to be postponed as she was now based in her home country of South Africa, and said she could not apply for a visa to return to the UK until later in the year and internet access in her location was poor.
However, the Committee found that the RCVS had properly served the notice of inquiry to Dr Bohnen in accordance with the current rules, that she had had sufficient time and opportunity to apply for a visa since receiving the notice and that, in any case, she could remotely ‘attend’ the hearing via Skype or telephone if necessary by travelling to somewhere that did have adequate internet connectivity, and so it refused the application.
The Disciplinary Committee then considered the facts of the case and heard evidence from the owners of Belle, the clinical director of the practice that Dr Bohnen worked in at the relevant time and a veterinary nurse, who was a student doing her training at the practice during the time of the events in question.
Having considered all of the evidence, the Committee dismissed the parts of the first charge relating to considering alternative treatment options and updating the owners in relation to Belle’s condition. They did, however, find the charge proven in relation to Dr Bohnen failing to assist Belle with urination.
The Committee found all aspects of the second charge proven in its entirety after Dr Bohnen admitted in advance of the hearing, that her representations were false and misleading.
The Committee then went on to consider whether the second charge and the aspects of the first charge that were found proven amounted to serious professional misconduct both individually and cumulatively.
The Committee considered that Dr Bohnen’s conduct in failing to assist Belle with urination, whilst falling below the standard to be expected of a reasonably competent veterinary surgeon, did not amount to serious professional misconduct.
The Committee did however find that Dr Bohnen’s conduct with regards to the second charge constituted serious professional misconduct.
Professor Alistair Barr, chairing the Committee and speaking on its behalf, said: "The Committee considers that the respondent’s dishonesty was the prime aggravating factor in this case. Although overall it could be regarded as a single incident, the Committee has found that it involved the fabrication of a number of notes and clinical records in the immediate aftermath of the death of the dog, but, thereafter, the respondent continued to deny the falsity of the fabricated records that she had created up to and until the conclusion of her interview by the practice on 30 March 2017.
"During that time, the respondent had contacted the alarm company responsible for the security of the premises of the practice, to enquire whether the security system would record the times of the alarm being switched on and off. This indicated that the respondent’s dishonesty continued over a significant period of time, and that her persistence in sticking to her story became premeditated. In other words, the respondent’s conduct over this time indicated a clear attempt to deceive."
Regarding the sanction for Dr Bohnen, the Committee considered that the principle aggravating factors in the case were serious dishonesty towards both her colleagues and the owners of the dog and involved clear breaches of the Code of Professional Conduct. By way of mitigation, the Committee noted that Dr Bohnen is of previous good character with no other professional findings against her and that she had demonstrated some insight into her behaviour and had admitted being dishonest and misleading prior to the hearing.
Summing up, Professor Barr said: "Because of the seriousness of this case, the Committee did not consider that it was appropriate to postpone judgement, take no further action, or to administer a reprimand and warning as to future conduct. The Committee considered that the respondent’s conduct, involving significant and admitted dishonesty over a period of time, required a significant penalty, in order to protect the welfare of animals and to serve the public interest.
"Accordingly, the Committee has decided to direct that the respondent’s registration be suspended for a period of nine months."
Dr Bohnen has 28 days from being informed of the Committee’s decision to lodge an appeal with the Privy Council.
Whilst you're here, take a moment to see our latest job opportunities for vets.
There's a complimentary counter top unit and pillow packs to help veterinary surgeons and nurses communicate the benefits of probiotics to clients. The unit can hold a cat and dog 30 sachet box of Purina Pro Plan FortiFlora from practice stock and the pillow packs can be used to dispense single sachets, so the client can trial the product with their pet at home.
At the same time, the company is encouraging vets and nurses to look at the evidence behind the probiotics they recommend. Although carried out a while ago now (2003 and 2011), two studies have shown that other diets claiming to contain probiotics generally did not meet the label claim when evaluated1,2.
Libby Sheridan, MVB MRCVS, Purina Veterinary Technical Affairs Manager, UK & Ireland says the efficacy of probiotics is thought to be strain-specific3 and recommends that clinicians critically assess the evidence for the particular strain and preparation of probiotics stocked or used.
Libby said: "The quality and efficacy of probiotics can vary and while in some cases there is strong evidence for efficacy in the targeted species, for others, the evidence is scant. Having experienced it myself, I know it's not always easy when working in a busy practice to take the time to ensure the evidence is there, but the studies back up that we should assess these things carefully before making a robust recommendation to our clients."
Most of the probiotics commercially available to veterinary professionals use the lactic acid bacterium Enterococcus faecium.
The particular strain and preparation of any probiotic will affect its ability to reach the large intestine, the expected site of action, intact. The evidence for the SF68 strain of Enterococcus faecium has been validated in a number of studies4-11 over recent years. Proven benefits of the SF68 strain include those focused on the gastrointestinal system where it supports canine and feline intestinal health and microflora balance and those with wider implications, such as support for a healthy immune system.
To obtain a unit or discuss the science, contact your Purina Veterinary Nutrition Partner or telephone the Purina Veterinary Nutrition Team on 0800 212161 quoting code VETPRESS.
Trodax is used to treat the mature and late-immature stages of the liver fluke Fasciola hepatica in both cattle and sheep. It is also indicated for the treatment of Haemonchus contortus infections.
Findlay MacBean, Business Head for Ruminant, at Boehringer Ingelheim Animal Health said: “Manufacturing problems have led to Trodax being out of stock since late 2020 and it is with regret that we have to confirm that we are no longer able to manufacture the product.
"As one of the largest animal health businesses in the world we are committed to improving the lives and health of animals. We have a strong research and development focus, and a pipeline of potential products, including antiparasitics. We recognise that the discontinuation of Trodax may pose challenges for cattle and sheep producers where resistance to other flukicides has been confirmed.
“Our technical services team are on hand to support veterinary practice and animal health merchant customers as we make this change to our portfolio. Customers who have a technical enquiry should call 01344 746957 or email vetenquiries@boehringer-ingelheim.com.”
Boehringer says that its other wormer and flukicide brands are not affected and that Ivomec Super Injection, which contains ivermectin and clorsulon, provides an alternative treatment option for adult liver fluke in cattle and is also effective against gastrointestinal worm species, lungworm, and key external parasites.
First you need to complete your VetSurgeon Profile, in particular the last four sections: "Qualified at", "Interests", "Interested in collaborating on" (aka goals) and "Memberships".
Then visit VetSurgeon Connect and click the button marked "Share My Location". This will activate the map beneath, allowing you to see local colleagues with common interests. It will also pin you on the map, but only in front of logged in members of the site with whom you have a common interest.
One area of common interest is the connection between general practitioners and referral practitioners. Referral practitioners who have shared their location are pinned on the map and can be seen by general practitioners (who can also filter them by discipline).
It is hoped that this will help create a more vibrant referral marketplace, as it offers referral practitioners who do not have big marketing budgets a way to connect with local general practitioners.
The system also matches VetSurgeon members by a number of other criteria. So for example, if you specify 'Qualified at' in your profile, it will display anyone else who went to the same vet school. If you display a leisure interest like cycling in your profile, it'll display other vets in your area who also like cycling.
If you display a clinical interest, such as oncology, it'll show you others in the area with the same interest.
The same thing happens with 'Interested in collaborating on', which connects you with others working towards the same goals, which can be business goals like practice ownership or a learning goals, such as CPD or being a mentor/mentee.
Lastly, if you specify your membership of a special interest veterinary association, the system will show you other members who are in your area.
VetSurgeon Editor Arlo Guthrie said: "It’s kind of a professional matchmaking service designed to make it easier than ever before for veterinary surgeons and others to hook up and collaborate on all sorts of different things.
"It may be you think you know everyone you need to know in your area already. But so often we think we know people, then find out we didn’t know about a shared passion for something, whether it be a professional or a leisure interest. Indeed, I think the system could be just as useful in connecting members to go on a bike ride together as it is to help them collaborate on CPD or on achieving additional qualifications."
Chris Taylor from Swann-Morton said: "We are really pleased to be part of this initiative which should help to bring the veterinary community closer together through shared experiences and knowledge."
Arlo added: "I’m very grateful for Swann Morton’s support. If you are too, you can show it by visiting the company's website and having a quick browse of the latest products in its veterinary range at www.swann-morton.com."